Société ContraVir Pharmaceuticals Inc Nasdaq
Actions
US21234W1036
Recherche biotechnologique et médicale
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/01/16 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/10/19 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Daniel Trepanier
PRN | Corporate Officer/Principal | - | 03/10/19 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/05/13 |
Timothy Block
BRD | Director/Board Member | 69 | 26/11/13 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/06/22 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 0 | 1 688 | 0 | 0 | 99,89 % |
Action B | 1 | 5 473 126 | 5 467 205 ( 99,89 %) | 0 | |
Action C | 0 | 85 581 | 0 | 0 |
Coordonnées société
Hepion Pharmaceuticals, Inc.
399 Thornall Street 1st Floor
08837, Edison
+732 902 4000
http://www.hepionpharma.com![Adresse ContraVir Pharmaceuticals Inc](https://cdn.zonebourse.com/static/address/21162967.png)
Secteur
Varia. 1 janv. | Capi. | |
---|---|---|
+15,20% | 121 Md | |
+19,67% | 113 Md | |
+18,95% | 26,02 Md | |
-23,86% | 19,39 Md | |
-19,03% | 15,91 Md | |
-20,90% | 15,09 Md | |
-46,14% | 15,06 Md | |
+63,85% | 14,93 Md | |
+4,49% | 13,85 Md |